Francesca Urselli

Francesca Urselli

Auto-generated profile, based on publicly available information

Francesca Urselli

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2022 in The EMBO Journal
Verified
Journal Article
Open access
TKTetsushi Kataura
Tetsushi Kataura
EOElsje G Otten
Elsje G Otten
YRYoana Rabanal‐Ruiz
Yoana Rabanal‐Ruiz
EAElias Adriaenssens
Elias Adriaenssens
FUFrancesca Urselli
Francesca Urselli
VKViktor Korolchuk
Viktor Korolchuk
Mitophagy, the elimination of mitochondria via the autophagy‐lysosome pathway, is essential for the maintenance of cellular homeostasis. The best characterised mitophagy pathway is mediated by stabilisation of the protein kinase PINK1 and recruitment of the ubiquitin ligase Parkin to damaged mitochondria. Ubiquitinated mitochondrial surface proteins are recognised by autophagy receptors including NDP52 which initiate the formation of an autophagic vesicle around the mitochondria. Damaged mitochondria also generate reactive oxygen species (ROS) which have been proposed to act as a signal for mitophagy, however the mechanism of ROS sensing is unknown. Here we found that oxidation of NDP52 is essential for the efficient PINK1/Parkin‐dependent mitophagy. We identified redox‐sensitive cysteine residues involved in disulphide bond formation and oligomerisation of NDP52 on damaged mitochondria. Oligomerisation of NDP52 facilitates the recruitment of autophagy machinery for rapid mitochondrial degradation. We propose that redox sensing by NDP52 allows mitophagy to function as a mechanism of oxidative stress response.

19 January 2024 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
APAllyssa Phelps
Allyssa Phelps
DPDiego Pazos-Castro
Diego Pazos-Castro
FUFrancesca Urselli
Francesca Urselli
EGEmily Grydziuszko
Emily Grydziuszko
OMOlivia Mann-Delany
Olivia Mann-Delany
JKJoshua F. E. Koenig
Joshua F. E. Koenig

11 October 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
SKSami B. Kanaan
Sami B. Kanaan
FUFrancesca Urselli
Francesca Urselli
JRJerald P. Radich
Jerald P. Radich
JNJ. Lee Nelson
J. Lee Nelson
Increasing mixed chimerism (reemerging recipient cells) after allogeneic hematopoietic cell transplant (allo-HCT) can indicate relapse, the leading factor determining mortality in blood malignancies. Most clinical chimerism tests have limited sensitivity and are primarily designed to monitor engraftment. We developed a panel of quantitative polymerase chain reaction assays using TaqMan chemistry capable of quantifying chimerism in the order of 1 in a million. At such analytic sensitivity, we hypothesized that it could inform on relapse risk. As a proof-of-concept, we applied our panel to a retrospective cohort of patients with acute leukemia who underwent allo-HCT with known outcomes. Recipient cells in bone marrow aspirates (BMAs) remained detectable in 97.8% of tested samples. Absolute recipient chimerism proportions and rates at which these proportions increased in BMAs in the first 540 days after allo-HCT were associated with relapse. Detectable measurable residual disease (MRD) via flow cytometry in BMAs after allo-HCT showed limited correlation with relapse. This correlation noticeably strengthened when combined with increased recipient chimerism in BMAs, demonstrating the ability of our ultrasensitive chimerism assay to augment MRD data. Our technology reveals an underappreciated usefulness of clinical chimerism. Used side by side with MRD assays, it promises to improve identification of patients with the highest risk of disease reoccurrence for a chance of early intervention.

18 June 2026
Verified
Other
Open access
HCHaroldo J. Rodriguez Chevez
Haroldo J. Rodriguez Chevez
ARAllison J. Remington
Allison J. Remington
MGMatthew D. Gray
Matthew D. Gray
RARian Alam
Rian Alam
MGMacy W. Gilmour
Macy W. Gilmour
JTJustin J. Taylor
Justin J. Taylor
Additional analyses of CD4+ T cells in MCC tumors.

18 June 2026
Verified
Other
Open access
PDF file
HCHaroldo J. Rodriguez Chevez
Haroldo J. Rodriguez Chevez
ARAllison J. Remington
Allison J. Remington
MGMatthew D. Gray
Matthew D. Gray
RARian Alam
Rian Alam
MGMacy W. Gilmour
Macy W. Gilmour
JTJustin J. Taylor
Justin J. Taylor
The frequency of T-Ag-specific B cells in the blood does not associate with levels of T-Ag-specific antibodies in the blood or outcome.

18 June 2026
Verified
Other
Open access
HCHaroldo J. Rodriguez Chevez
Haroldo J. Rodriguez Chevez
ARAllison J. Remington
Allison J. Remington
MGMatthew D. Gray
Matthew D. Gray
RARian Alam
Rian Alam
MGMacy W. Gilmour
Macy W. Gilmour
JTJustin J. Taylor
Justin J. Taylor
Multiplex immunohistochemistry staining of MCC tumor microarrays.